Shilpa Medicare Limited (BOM:530549)

Market Cap	168.44B +133.4%
Revenue (ttm)	16.83B +28.0%
Net Income	2.97B +167.6%
EPS	15.20 +167.4%
Shares Out	195.58M
PE Ratio	56.67
Forward PE	52.37
Dividend	0.60 (0.07%)
Ex-Dividend Date	Sep 4, 2026

Volume	64,647
Open	839.95
Previous Close	844.95
Day's Range	821.00 - 893.50
52-Week Range	260.00 - 1,095.65
Beta	0.35
Analysts	Buy
Price Target	881.25 (+2.32%)
Est. Earnings	Nov 6, 2026

About Shilpa Medicare

Shilpa Medicare Limited offers pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation (CDMO) services in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, d...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 1987
• Employees: 1,241
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 530549

Financial Performance

In fiscal year 2026, Shilpa Medicare's revenue was 15.40 billion, an increase of 19.60% compared to the previous year's 12.88 billion. Earnings were 2.43 billion, an increase of 210.81%.

Analyst Summary

According to 4 analysts, the average rating for 530549 stock is "Buy." The 12-month stock price target is ₹881.25, which is an increase of 2.32% from the latest price.

Price Target

₹881.25

(2.32% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 23, 2026

Data Sources Report a data error